295 related articles for article (PubMed ID: 35403792)
1. Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users.
Arrieta A; Battelino T; Scaramuzza AE; Da Silva J; Castañeda J; Cordero TL; Shin J; Cohen O
Diabetes Obes Metab; 2022 Jul; 24(7):1370-1379. PubMed ID: 35403792
[TBL] [Abstract][Full Text] [Related]
2. Predictors of time in target glucose range in real-world users of the MiniMed 780G system.
Castañeda J; Mathieu C; Aanstoot HJ; Arrieta A; Da Silva J; Shin J; Cohen O
Diabetes Obes Metab; 2022 Nov; 24(11):2212-2221. PubMed ID: 35791621
[TBL] [Abstract][Full Text] [Related]
3. Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users.
Silva JD; Lepore G; Battelino T; Arrieta A; Castañeda J; Grossman B; Shin J; Cohen O
Diabetes Technol Ther; 2022 Feb; 24(2):113-119. PubMed ID: 34524003
[No Abstract] [Full Text] [Related]
4. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system.
Grassi B; Gómez AM; Calliari LE; Franco D; Raggio M; Riera F; Castro M; McVean J; van den Heuvel T; Arrieta A; Castañeda J; Cohen O
Diabetes Obes Metab; 2023 Jun; 25(6):1688-1697. PubMed ID: 36789699
[TBL] [Abstract][Full Text] [Related]
5. One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes.
Bassi M; Patti L; Silvestrini I; Strati MF; Ponzano M; Minuto N; Maggi D
Front Endocrinol (Lausanne); 2023; 14():1099024. PubMed ID: 36777356
[TBL] [Abstract][Full Text] [Related]
6. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
Benhalima K; Beunen K; Van Wilder N; Ballaux D; Vanhaverbeke G; Taes Y; Aers XP; Nobels F; Marlier J; Lee D; Cuypers J; Preumont V; Siegelaar SE; Painter RC; Laenen A; Gillard P; Mathieu C
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):390-403. PubMed ID: 38697182
[TBL] [Abstract][Full Text] [Related]
7. Real-world performance of the MiniMed™ 670G system in Europe.
Da Silva J; Bosi E; Jendle J; Arrieta A; Castaneda J; Grossman B; Cordero TL; Shin J; Cohen O
Diabetes Obes Metab; 2021 Aug; 23(8):1942-1949. PubMed ID: 33961340
[TBL] [Abstract][Full Text] [Related]
8. MiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users.
Elbarbary NS; Ismail EAR
Diabetol Metab Syndr; 2023 Oct; 15(1):205. PubMed ID: 37845757
[TBL] [Abstract][Full Text] [Related]
9. Safety and Glycemic Outcomes During the MiniMed
Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
[No Abstract] [Full Text] [Related]
10. 12-Month Real-Life Efficacy of the MiniMed 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.
Lablanche S; Delagenière J; Jalbert M; Sonnet E; Benichou M; Arnold N; Spiteri A; Le Berre JP; Renard E; Chevalier N; Borot S; Bonnemaison E; Coffin C; Teissier MP; Benhamou PY; Borel JC; Penfornis A; Joubert M; Kessler L
Diabetes Technol Ther; 2024 Jun; 26(6):426-432. PubMed ID: 38236643
[No Abstract] [Full Text] [Related]
11. Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI).
Petrovski G; Al Khalaf F; Campbell J; Day E; Almajaly D; Hussain K; Pasha M; Umer F; Hamdan M; Khalifa A
BMC Endocr Disord; 2022 Mar; 22(1):80. PubMed ID: 35351095
[TBL] [Abstract][Full Text] [Related]
12. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.
Cordero TL; Dai Z; Arrieta A; Niu F; Vella M; Shin J; Rhinehart AS; McVean J; Lee SW; Slover RH; Forlenza GP; Shulman DI; Pop-Busui R; Thrasher JR; Kipnes MS; Christiansen MP; Buckingham BA; Pihoker C; Sherr JL; Kaiserman KB; Vigersky RA
Diabetes Technol Ther; 2023 Sep; 25(9):652-658. PubMed ID: 37252734
[No Abstract] [Full Text] [Related]
13. Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience.
Halim B; Abraham MB; Manos G; Arrieta A; Dai Z; Vogrin S; Lu J; MacIsaac R; Ekinci EI; Davis EA; Jenkins A; Shin J; Vigersky RA; Jones TW; O'Neal D
Diabetes Technol Ther; 2024 Mar; 26(3):190-197. PubMed ID: 38444313
[No Abstract] [Full Text] [Related]
14. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
[No Abstract] [Full Text] [Related]
15. The Medtronic 780G advanced hybrid closed-loop system achieves and maintains good glycaemic control in type 1 diabetes adults despite previous treatment.
Quirós C; Alonso-Carril N; Rodríguez-Rodríguez S; Barahona MJ; Orois A; Simó-Servat A; Ramos M; Perea V
Endocrinol Diabetes Nutr (Engl Ed); 2023 Feb; 70(2):130-135. PubMed ID: 36925230
[TBL] [Abstract][Full Text] [Related]
16. MiniMed 780GTM in children with type 1 diabetes under seven years of age: Prospective open-label, single-arm, double-center, follow-up study.
Seget S; Chobot A; Rusak E; Ochab A; Bielawska A; Polanska J; Jarosz-Chobot P
Technol Health Care; 2024; 32(3):1463-1472. PubMed ID: 37781828
[TBL] [Abstract][Full Text] [Related]
17. Body mass index, basal insulin and glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system remain stable - 1-year prospective, observational, two-center study.
Seget S; Jarosz-Chobot P; Ochab A; Polanska J; Rusak E; Witoszek P; Chobot A
Front Endocrinol (Lausanne); 2022; 13():1036808. PubMed ID: 36303875
[TBL] [Abstract][Full Text] [Related]
18. MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control.
Lombardo F; Passanisi S; Alibrandi A; Bombaci B; Bonfanti R; Delvecchio M; Di Candia F; Mozzillo E; Piccinno E; Piona CA; Rigamonti A; Scialabba F; Maffeis C; Salzano G
Diabetes Technol Ther; 2023 Jun; 25(6):404-413. PubMed ID: 36763343
[No Abstract] [Full Text] [Related]
19. Improved Satisfaction While Maintaining Safety and High Time in Range (TIR) With a Medtronic Investigational Enhanced Advanced Hybrid Closed-Loop (e-AHCL) System.
Yuan CY; Kong YW; Amoore T; Brown K; Grosman B; Jenkins A; Jones H; Kurtz N; Lee MH; MacIsaac R; Netzer E; Paldus B; Robinson L; Roy A; Sims CM; Trawley S; Vogrin S; O'Neal DN
Diabetes Care; 2024 Apr; 47(4):747-755. PubMed ID: 38381515
[TBL] [Abstract][Full Text] [Related]
20. MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience.
Rachmiel M; Lebenthal Y; Mazor-Aronovitch K; Brener A; Levek N; Jacobi-Polishook T; Ben Ari T; Abiri S; Landau Z; Pinhas-Hamiel O
Diabetes Technol Ther; 2023 Sep; 25(9):643-651. PubMed ID: 37219952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
